Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 11th Consecutive Year

ACCESS Newswire
25 Feb

SECAUCUS, NJ / ACCESS Newswire / February 24, 2025 / Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, recently announced that it has been selected as one of the 2025 World's Most Admired Companies™ by Fortune® magazine, the 11th consecutive year the company has been named to the elite list of globally respected companies.

The selection is based on nine key attributes related to corporate reputation, including quality of products and services, innovation, community responsibility, social responsibility, and talent management.

"Every day, the more than 55,000 colleagues of Quest Diagnostics bring our purpose to life: working together to create a healthier world, one life at a time," said Jim Davis, Chairman, CEO and President. "Their commitment to living our purpose in service to our customers and patients is the reason we continue to be recognized among Fortune's World's Most Admired Companies."

In addition to the overall ranking, Quest was number three in the "Health Care: Pharmacy and Other Services" industry category. Quest ranked in the top 1 or 2 spot of seven of nine criteria that comprise the industry category, including quality of management, long-term investment, product and service quality, social responsibility and people management.

Consulting firm Korn Ferry collaborated with Fortune to survey thousands of executives, directors and analysts who rated companies in their industry on nine criteria, analyzing a total of 650 companies. A company's score must rank in the top half of its industry survey to be listed as a World's Most Admired Company.

Find more information on the 2025 Fortune's World's Most Admired Companies here.

About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.

SOURCE Quest Diagnostics

For further information: For further information: Jill Flanagan, Quest Diagnostics (Media): 973-520-2800 or mediacontact@QuestDiagnostics.com; Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900

View additional multimedia and more ESG storytelling from Quest Diagnostics on 3blmedia.com.

Contact Info:
Spokesperson: Quest Diagnostics
Website: https://www.3blmedia.com/profiles/quest-diagnostics
Email: info@3blmedia.com

SOURCE: Quest Diagnostics



View the original press release on ACCESS Newswire

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10